Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation

Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation

Detalhes bibliográficos
Main Authors:	Fairclough, R, Davies, K
Formato:	Conference item
Publicado em:	2010

Registos relacionados

Utrophin upregulation in Duchenne muscular dystrophy.
Por: Hirst, R, et al.
Publicado em: (2005)

Utrophin upregulation in DMD therapy: current status and new tools for the future
Por: Fairclough, R, et al.
Publicado em: (2011)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
Por: Fairclough, R, et al.
Publicado em: (2012)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
Por: Fairclough, R, et al.
Publicado em: (2008)

Characterisation of utrophin modulator SMT C1100 as a non-competitive inhibitor of firefly luciferase
Por: Wilkinson, I, et al.
Publicado em: (2019)

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
Por: Tinsley, J, et al.
Publicado em: (2011)

Non-toxic ubiquitous overexpression of utrophin in the mdx mouse.
Por: Fisher, R, et al.
Publicado em: (2000)

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.
Por: Sewry, C, et al.
Publicado em: (2005)

Regulation of utrophin in transgenic mice.
Por: Davies, K
Publicado em: (2005)

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
Por: Chancellor, DR, et al.
Publicado em: (2011)

Understanding the endothelial function of utrophin.
Por: Ehmsen, J, et al.
Publicado em: (2002)

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.
Por: Fisher, R, et al.
Publicado em: (2001)

Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research
Por: Bareja, A
Publicado em: (2011)

Towards the elucidation of the mechanism of action of small molecule upregulators of utrophin using chemical proteomics
Por: Vuorinen, A
Publicado em: (2017)

Utrophin in the therapy of Duchenne Muscular Dystrophy
Por: Potter, A, et al.
Publicado em: (2006)

Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
Por: Sang, E, et al.
Publicado em: (2000)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
Por: Griffin, J, et al.
Publicado em: (2002)

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
Por: Wakefield, P, et al.
Publicado em: (2000)

Utrophin in therapy of Duchenne muscular distrophy
Por: Fisher, R
Publicado em: (2001)

Regulation of utrophin in transgenic mice (multiple letters)
Por: Davies, K, et al.
Publicado em: (2005)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
Por: Perkins, K, et al.
Publicado em: (2002)

Second-generation compound for the modulation of utrophin in the therapy of DMD
Por: Guiraud, S, et al.
Publicado em: (2015)

The utrophin and dystrophin genes share similarities in genomic structure.
Por: Pearce, M, et al.
Publicado em: (1993)

Immunogold confirmation that utrophin is localized to the normal position of dystrophin in dystrophin-negative transgenic mouse muscle.
Por: Culle, M, et al.
Publicado em: (2001)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
Por: Tinsley, J, et al.
Publicado em: (2013)

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.
Por: Li, D, et al.
Publicado em: (2010)

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin
Por: Li, D, et al.
Publicado em: (2010)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
Por: Kennedy, T, et al.
Publicado em: (2017)

Confirmation by immunogold labeling that utrophin is localised to the normal position of dystrophin in dystrophin-negative transgenic mouse muscle
Por: Cullen, M, et al.
Publicado em: (2001)

Identification of serum protein biomarkers for utrophin based DMD therapy.
Por: Guiraud, S, et al.
Publicado em: (2017)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
Por: Guiraud, S, et al.
Publicado em: (2019)

Heregulin-induced epigenetic regulation of the utrophin-A promoter.
Por: Basu, U, et al.
Publicado em: (2007)

Utrophin up-regulation by an artificial transcription factor in transgenic mice
Por: Mattei, E, et al.
Publicado em: (2007)

A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration.
Por: Weir, A, et al.
Publicado em: (2004)

A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin.
Por: Cole, M, et al.
Publicado em: (2002)

ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan.
Por: Ishikawa-Sakurai, M, et al.
Publicado em: (2004)

Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure.
Por: Rafael, J, et al.
Publicado em: (2000)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
Por: Fairclough, R, et al.
Publicado em: (2014)

Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
Por: Guiraud, S, et al.
Publicado em: (2018)

Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy
Por: Sewry, C, et al.
Publicado em: (2004)